Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
im inclined to agree. great company with analyst upgrades!
Loading up and getting ready to lock in!... this is going to be a big gainer!
I agree. analysts are raising their targets on this one as well. And yes , I said ANALYSTS still on this one! 4.00 easy by mid summer
SHORT TERM $$$100%$$$ GAINER EASY.. Do your DD This is golden. $4 by end of June
Nice rebound starting off the bottom here
For some reason it's a glitch in iHub's app that need to be fixed.
Hey Clay your video links don't show up on my mobile FYI. Any idea why?
* * $VSTM Video Chart 05-08-2020 * *
Link to Video - click here to watch the technical chart video
This is primed to move up in the coming days... need to break 2 and hold.. then we should test 3s
I like what I see here. Picked up position.
* * $VSTM Video Chart 05-04-2020 * *
Link to Video - click here to watch the technical chart video
* * $VSTM Video Chart 04-27-2020 * *
Link to Video - click here to watch the technical chart video
Where is the bottom here?
* * $VSTM Video Chart 04-20-2020 * *
Link to Video - click here to watch the technical chart video
Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that management will host an investor conference call to discuss the clinical data from the ongoing investigator-initiated study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant advanced solid tumors. The conference call coincides with the presentation of this data at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The investor conference call is scheduled for Monday, April 27, 2020 at 8:00 a.m. ET.
The call will feature members of the Company’s management team and Udai Banerji, MBBS, MD, DNB, PhD, FRCP, NIHR Professor of Molecular Cancer Pharmacology at The Institute of Cancer Research and Honorary Consultant in Medical Oncology at The Royal Marsden NHS Foundation Trust, and lead investigator of the clinical study. This is an ongoing investigator-initiated open label, dose escalation and expansion study. Expansion cohorts are currently ongoing in patients with KRAS mutant advanced solid tumors, including low grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Verastem Oncology plans to initiate discussions with regulatory authorities during the first half of 2020, with the goal of commencing a registration-directed trial investigating the VS-6766/defactinib combination as soon as possible.
Details for the AACR 2020 Virtual Meeting I presentation are as follows:
Title: Phase 1 study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers
Lead author: Udai Banerji, Institute of Cancer Research and The Royal Marsden
Poster #: CT143
Session: VPO.CT01 - Phase I Clinical Trials
Date and Time: Monday, April 27, 2020; 9:00 a.m. to 6:00 p.m. ET
URL: https://www.abstractsonline.com/pp8/#!/9045/presentation/10642
Conference Call and Webcast Information
The Verastem Oncology management team will host a conference call and webcast on Monday, April 27, 2020, at 8:00 AM ET to discuss the Phase 1 RAF/MEK/FAK combination data. The call can be accessed by dialing (877) 341-5660 (U.S. and Canada) or (315) 625-3226 (international), five minutes prior to the start of the call and providing the passcode 8390795.
The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Company's website at www.verastem.com. A replay of the webcast will be archived on the Company's website for 90 days following the call.
About VS-6766
VS-6766 (formerly known as CH5126766, CKI27 and RO5126766) is a unique inhibitor of the RAF/MEK signaling pathway. In contrast to other MEK inhibitors in development, VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. This unique mechanism allows VS-6766 to block MEK signaling without the compensatory activation of MEK that appears to limit the efficacy of other inhibitors. The combination of VS-6766 and the focal adhesion kinase (FAK) inhibitor defactinib is currently being investigated in a Phase 1 dose escalation and expansion study. The expansion cohorts are currently ongoing in patients with KRAS mutant advanced solid tumors, including low grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).1 The ongoing clinical study of the VS-6766/defactinib combination is supported by single-agent Phase 2 studies which investigated defactinib in KRAS mutant NSCLC2 and VS-6766 in KRAS mutant NSCLC and LGSOC.3
About Defactinib
Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is currently being evaluated as a potential combination therapy for various solid tumors. The Company has received Orphan Drug designation for defactinib in ovarian cancer and mesothelioma in the US, EU and Australia. Preclinical research by Verastem Oncology scientists and collaborators at world-renowned research institutions has described the effect of FAK inhibition to enhance immune response by decreasing immuno-suppressive cells, increasing cytotoxic T cells, and reducing stromal density, which allows tumor-killing immune cells to enter the tumor.4,5 Additionally, in both preclinical and clinical studies, FAK activation has been shown to occur as a potential resistance mechanism in response to MEK inhibitor treatment, and synergy of a FAK inhibitor with a RAF/MEK inhibitor has been shown in several preclinical models. The combination of defactinib and VS-6766 is currently being investigated in a Phase 1 dose escalation and expansion study. The expansion cohorts are currently ongoing in patients with KRAS mutant advanced solid tumors, including low grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).1 The ongoing clinical study of the VS-6766/defactinib combination is supported by single-agent Phase 2 studies which investigated defactinib in KRAS mutant NSCLC2 and VS-6766 in KRAS mutant NSCLC and LGSOC.3 Defactinib is also in clinical testing in combination with pembrolizumab for treatment of patients with pancreatic cancer, NSCLC and mesothelioma.6
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK) and RAF/MEK inhibition.
Our first FDA approved product is available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).
For more information, please visit www.verastem.com.
https://www.businesswire.com/news/home/20200420005157/en/
There are supposed data results from the studies performed released in Mid-late April from what I'm hearing.
Hold tight, this could be a big one in 2-3 years. I am buying shares on every dip.
When is the next catalyst for this stock?
Perhaps they are setting their position for larger goals that require a bit more capital. Did you see the number of investment firms who are getting in at this level? Trial data due in around the end of April?
This is my most promising Biotech, their upside with a KRAS breakthrough is a 10+ bagger from here.
Company has enough cash to pay the bills for about 3 quarters. I don't like that the board is having a vote in April in order to authorize another 100 million shares. Other than to raise more capital, what other reason would they do this? Three years ago this company was trading around $8. I think dilution brought this down. I'm long and strong on this but trying to understand the strategy.
Verastem, Inc. (VSTM) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Verastem, Inc. (VSTM). The stock has moved higher by 38.5% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
We certainly think that this might be the case, particularly if you consider VSTM’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as VSTM has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.
https://finance.yahoo.com/news/verastem-inc-vstm-shares-march-132801752.html?.tsrc=rss
Just got on and saw that...nice
Like clockwork, the run has begun!
Breakout is imminent!
Brace yourselves for solids gains.
That could be a very nice ticket...good luck!
I bought some 3/20 $3.00 calls @ .20 this morning on that dip in anticipation of earnings on the 13th, this stock could explode.
Huge potential here. $VSTM best of the best stock for 2020 in my opinion . Could be next $MRTX with new financing and data in few weeks .
* * $VSTM Video Chart 02-28-2020 * *
Link to Video - click here to watch the technical chart video
Definitely! I got in at $1.28...looking for 1000%
good play bud hold long - I am in at 1.25
Very nice! Daddy likes...especially with the stock market this week. Only thing saving me.
Got Stopped Out @ 2.22 From 2.15 Entry Profit Secured. GLTY $$$
You’re not a lone...I purchased this back on Jan 7th for $1.28...Boom!!!
Cheers to us...
Let’s go!
* * $VSTM Video Chart 02-04-2020 * *
Link to Video - click here to watch the technical chart video
2.17 Go Full Blast Buying now or cry again chasing above 2.50's LOL $$$
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
797
|
Created
|
02/01/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |